In conclusion, our preclinical data in HNSCC provide both a unique view of EGFR, HER2, and ErbB3 signaling and a mechanistic rationale to combine EGFR and ErbB3-targeting therapies for the treatment of this tumor type. The gene discussed is EGFR; the disease is head and neck squamous cell carcinoma.